IP Library Granted Patent US 12,098,118
Granted Patent B2
US 12,098,118 · App. 17/291,345 · Granted Sep 24, 2024

Analgesic and anti-addictive compositions for treatment of chronic pain and opioid addiction

Inventors: Carolyn A. Fairbanks (Minneapolis, MN); Herbert T. Nagasawa (Minneapolis, MN); George L. Wilcox (Minneapolis, MN); Cristina D. Peterson (Minneapolis, MN); Kelley F. Kitto (Minneapolis, MN)
Assignee: Regents of the University of Minnesota
C07C279/24C07C279/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,098,118
App. No.
17/291,345
Granted
Sep 24, 2024
Kind
B2
Abstract

The invention provides a compound of formula I and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the formula I compounds, as well as methods of using such as therapeutic agents for the treatment of pain-related disorders and diseases and in combination with other therapeutic agents.

Claims (18)

1. A compound selected from:

ethyl (amino((4-((ethoxycarbonyl)amino)butyl)amino)methylene)carbamate;

ethyl (4-guanidinobutyl)carbamate;

4-(2,3-bis(ethoxycarbonyl)guanidino)butylacetamide;

4-(2,3-bis(tert-butyloxycarbonyl)guanidino)butylacetamide;

4-(2-(ethoxycarbonyl)guanidino)butylacetamide;

4-(2-(ethoxycarbonyl)guanidino)butan-1-aminium 2,2,2-trifluoroacetate;

4-(2,3-bis(ethoxycarbonyl)guanidino)butan-1-aminium chloride;

4-(2,3-bis(ethoxycarbonyl)guanidino)butan-1-aminium 2,2,2-trifluoroacetate;

16-carboxy-6-((ethoxycarbonyl)amino)-4, 13-dioxo-3-oxa-5,7,12-triazahexadec-5-en-16-aminium 2,2,2-trifluoroacetate;

(16S,21R)-21-amino-16-((carboxymethyl)carbamoyl)-6-imino-4,13,18-trioxo-3-oxa-14-thia-5,7,12,17-tetraazadocosan-22-oic acid;

21-amino-16-carboxy-6-((ethoxycarbonyl)amino)-4,13,18-trioxo-3-oxa-5,7,12,17-tetraazadocos-5-en-22-oic acid; and

6-imino-4, 13-dioxo-3-oxa-5,7,12-triazatetracosane,

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a compound as described in claim 1 and a pharmaceutically acceptable excipient.

3. A method for treating pain in an animal comprising administering the pharmaceutical composition of claim 2 to the animal.

4. A method for treating or preventing opioid analgesic tolerance, neuropathic pain, and opioid analgesic addiction in an animal comprising administering a compound as described in claim 1 , or a pharmaceutically acceptable salt thereof to the animal.

5. The method of claim 4 wherein the compound is administered intrathecally.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2023
From: FAIRBANKS, CAROLYN A.; NAGASAWA, HERBERT T.; WILCOX, GEORGE L.; PETERSON, CRISTINA D.; KITTO, KELLEY F.
To: REGENTS OF THE UNIVERSITY OF MINNESOTA
Reel/Frame 062845/0204 →
CONFIRMATORY LICENSE Recorded Jan 6, 2022
From: MCNAMARA ALUMNI CENTER
To: THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE ARMY
Reel/Frame 058649/0928 →
Continuity (2)
Provisional Application 62756883 · Nov 7, 2018
Related Publication 20220002238A1 · Jan 6, 2022